---
title: "减重版司美格鲁肽新研究公布：多数体重减轻是体脂减少 肌肉功能不影响"
description: "诺和诺德在 2025 年欧洲糖尿病研究协会年会公布的 STEP UP 试验显示，接受高剂量司美格鲁肽治疗的受试者平均体重降幅达 21%，其中三分之一受试者降幅超过 25%。研究表明，体重减轻主要为体脂减少，且与安慰剂组相比，瘦体重和肌肉量变化无显著差异，肌肉功能保持良好。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/258033080.md"
published_at: "2025-09-19T07:27:34.000Z"
---

# 减重版司美格鲁肽新研究公布：多数体重减轻是体脂减少 肌肉功能不影响

> 诺和诺德在 2025 年欧洲糖尿病研究协会年会公布的 STEP UP 试验显示，接受高剂量司美格鲁肽治疗的受试者平均体重降幅达 21%，其中三分之一受试者降幅超过 25%。研究表明，体重减轻主要为体脂减少，且与安慰剂组相比，瘦体重和肌肉量变化无显著差异，肌肉功能保持良好。

诺和诺德在 2025 年欧洲糖尿病研究协会年会公布了多个研究成果。其中，STEP UP 试验表明，接受更高剂量诺和盈治疗的受试者相较于安慰剂组实现平均 21% 的体重降幅，其中三分之一的受试者体重降幅达 25% 或以上。在 STEP UP 试验中，司美格鲁肽 7.2 mg 实现的体重减轻主要为体脂减少。STEP UP 试验亚组分析结果表明，接受司美格鲁肽 7.2 mg 治疗的受试者的瘦体重及肌肉量的变化相比于安慰剂组无显著差异，且肌肉功能也得以保持。

### Related Stocks

- [NVO.US - 诺和诺德公司](https://longbridge.com/zh-CN/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| US sugar industry weighs impact from new dietary guidelines regulation | The U.S. sugar industry is facing potential impacts from new dietary guidelines that may reduce domestic sugar demand. S | [Link](https://longbridge.com/zh-CN/news/276479104.md) |
| Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound | Novo Nordisk's high-dose version of Wegovy received a positive recommendation from the EU's drug advisory board, potenti | [Link](https://longbridge.com/zh-CN/news/269559288.md) |
| CSPC Pharmaceutical Group Limited Obtains Approval from the U.S. Food and Drug Administration to Conduct Clinical Trials in the U.S | CSPC Pharmaceutical Group Limited has received FDA approval to conduct clinical trials in the U.S. for its GLP-1/GIP rec | [Link](https://longbridge.com/zh-CN/news/276050786.md) |
| Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports | Feb 19 (Reuters) - Johnson & Johnsonis preparing a potential sale of the orthopedics unit that it has been planning to s | [Link](https://longbridge.com/zh-CN/news/276370994.md) |
| FDA Approves Novo Nordisk Wegovy Pill as First Oral GLP-1 for Weight Management | Novo Nordisk's Wegovy® pill, the first oral GLP-1 receptor agonist for weight management, has been approved by the FDA.  | [Link](https://longbridge.com/zh-CN/news/270541194.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
